Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Business Description: Global pharmaceutical company with a leading position in diabetes/obesity and a rich pipeline of follow-on medicines addressing several therapeutic categories. Thesis: Lilly is...
— Alan Breed
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Eli Lilly and Company
We also continued to add to Eli Lilly and Company in the third quarter. Lilly is best...
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
Eli Lilly is a premier multinational pharmaceutical company engaged in the research, development, and commercialization of therapeutics, currently dominating the global market for diabetes and obesity treatments. The manager is...
More institutional theses from Edgewood Management
Nvidia and Eli Lilly are two examples from our portfolio. Nvidia spent years...
As the primary industry standard in consumer credit scoring, the company holds an incredibly durable market position. Recent regulatory headline...
Boasting a near-monopoly in crucial photolithography technology, the company is an essential beneficiary of secular semi-conductor growth. Short-term stock declines...